Jazz Pharmaceuticals (JAZZ) Could Be 27% Undervalued As Record Revenue Lifts Outlook

What happened: Jazz Pharmaceuticals ($JAZZ) reported third quarter 2026 results with record revenue and a swing to a sizeable loss, while raising its full year revenue outlook and highlighting newly approved cancer drug Ziihera. Key numbers: Last close $214.44. Why it matters: The narrative frames the discount around oncology execution and cash flow durability rather than short term earnings noise, with Ziihera expansion into additional HER2 driven tumors seen as a potential new revenue stream. Patent cliffs in sleep medicine and tougher oncology competition are cited as risks to that view. Market: -0.7% today ($214.44), +23.8% YTD, 1.2x vol — as of 11:45 UTC Verified: Q3_2026 (Nov 2) EPS $-7.48 vs $-2.21 est, -238.6% miss; next print ~Feb 1

Jazz Pharmaceuticals ($JAZZ) reported third quarter 2026 results with record revenue and a swing to a sizeable loss, while raising its full year revenue outlook and highlighting newly approved cancer drug Ziihera.

The narrative frames the discount around oncology execution and cash flow durability rather than short term earnings noise, with Ziihera expansion into additional HER2 driven tumors seen as a potential new revenue stream. Patent cliffs in sleep medicine and tougher oncology competition are cited as risks to that view. Market: -0.7% today ($214.44), +23.8% YTD, 1.2x vol — as of 11:45 UTC Verified: Q3_2026 (Nov 2) EPS $-7.48 vs $-2.21 est, -238.6% miss; next print ~Feb 1